Posted by Michael Wonder on 31 Aug 2021
ANI Pharmaceuticals announces FDA acceptance of purified Cortrophin gel supplemental new drug application for multiple indications including multiple sclerosis, rheumatoid arthritis and nephrotic syndrome
31 August 2021 - Prescription Drug User Fee Act target action date is 29 October 2021.
ANI Pharmaceuticals today announced that the Company’s supplemental new drug application for purified Cortrophin gel has been accepted by the U.S. FDA for review.
